Summary of Product Characteristics Updated 03-Jun-2020 | McNeil Products Ltd
Daktarin Aktiv Spray Powder
Miconazole nitrate 0.16% w/w
(Each gram of spray contains 1.6 mg of miconazole nitrate)
For excipients, see Section 6.1.
Cutaneous spray powder
Spray leaving a white powdery residue
Cutaneous administration for the treatment and prevention of athlete's foot.
Apply to infected area twice daily until the lesions are healed.
Method of administration: Cutaneous use
Hypersensitivity to the active substance(s), other imidazole derivatives or to any of the excipients listed in section 6.1
Not to be used on hair infections, nail infections or broken skin.
The spray should be kept away from the eyes and mucous membranes.
Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported during treatment with Daktarin Aktiv Spray Powder and with other miconazole topical formulations (see Adverse Reactions). If a reaction suggesting hypersensitivity or irritation should occur, the treatment should be discontinued.
Daktarin Aktiv Spray Powder contains talc. Avoid inhalation of the powder to prevent irritation of the airways. In particular, when treating infants and children, careful application should be used to prevent inhalation by the child.
Miconazole administered systemically is known to inhibit CYP3A4/2C9. Due to the limited systemic availability after topical application, clinically relevant interactions are rare. However, in patients on oral anticoagulants, such as warfarin, caution should be exercised and anticoagulant effect should be monitored.
In animals, miconazole nitrate has shown no teratogenic effects but is foetotoxic at high oral doses. Only small amounts of miconazole nitrate are absorbed following topical administration. However, as with other imidazoles, miconazole nitrate should be used with caution during pregnancy.
Topically applied miconazole is minimally absorbed into the systemic circulation and it is not known whether miconazole is excreted in human breast milk. Caution should be exercised when using topically applied miconazole products during lactation.
Adverse drug reactions from spontaneous reports during the worldwide postmarketing experience with Daktarin that meet threshold criteria are included. The adverse drug reactions are ranked by frequency, using the following convention:
Very common ≥ 1/10
Common ≥ 1/100 and < 1/10
Uncommon ≥ 1/1,000 and <1/100
Rare ≥ 1/10,000, < 1/1,000
Very rare < 1/10,000, including isolated reports
The frequencies provided below reflect reporting rates for adverse drug reactions from spontaneous reports, and do not represent more precise estimates of incidence that might be obtained in clinical or epidemiological studies.
Immune system disorders
Very rare: anaphylactic reaction, hypersensitivity,
Skin and subcutaneous tissue disorders
Very rare: Angioedema, urticaria, contact dermatitis, rash, erythema, pruritus, skin burning sensation
General disorders and administration site conditions
Rare: application site reactions, including application site irritation
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Cutaneous use: Excessive use can result in skin irritation, which usually disappears after discontinuation of therapy.
Daktarin Aktiv Spray Powder is intended for cutaneous use, not for oral use. If accidental ingestion of large quantities of the product occurs, an appropriate method of gastric emptying may be used if considered desirable.
Accidential inhalation of talc-containing powder: Massive accidental aspiration of Daktarin Aktiv Spray Powder may cause impaction blockage of airways. Respiratory arrest should be treated with intensive supportive therapy and oxygen. If respiration is compromised, endotracheal intubation, removal of impacted material, and assisted breathing should be considered.
Pharmacotherapeutic classification: (Antifungals for dermatological/topical use; imidazole derivative) ATC code: D01A C02.
Miconazole is an imidazole antifungal agent and may act by interfering with the permeability of the fungal cell membrane. It possesses a wide antifungal spectrum and has some antibacterial activity.
Absorption: There is little absorption through skin or mucous membranes when miconazole nitrate is applied topically.
Distribution: Absorbed miconazole is bound to plasma proteins (88.2%) and red blood cells (10.6%).
Metabolism and Excretion: The small amount of miconazole that is absorbed is eliminated predominantly in faeces as both unchanged drug and metabolites.
Preclinical data reveal no special hazard for humans based on conventional studies of local irritation, single and repeated dose toxicity, genotoxicity, and toxicity to reproduction.
Keep out of reach and sight of children.
Protect from light
Do not expose to temperatures exceeding 50°C
Three piece aerosol container with epoxy lining and welded side seam with protective polyester side strip.
1 inch opening to accommodate a standard aerosol valve.
The aerosol container contains 100g of product.
Shake well. Hold can 3 inches from skin, then generously spray affected area.
Pressurised container: Protect from sunlight and do not expose to temperatures exceeding 50°C.
Do not pierce or burn, even after use.
Do not spray on or near a naked flame or any incandescent material.
Keep away from sources of ignition - No smoking.
Do not spray near, or place on, polished or painted surfaces.
McNeil Products Limited
50 - 100 Holmers Farm Way
27 May 2020